On this page
Back to topLabcorp LH
Labcorp is the 319th largest S&P 500 company by market cap, worth $29.8 billion. Its board has 11 directors, 10 of them independent. 10 other officers are on file. At 30 Jun 2026, Vanguard was its largest institutional holder, with 12.1% of the company.
- Chair and CEO
- Adam H. Schechter
- Sector
- Health CareHealth Care Services
- Headquarters
- Burlington, North Carolina
- Founded
- 1978
- Market cap
- $29.8B
- 319th largest, 6 Nov 2026 close
- Price to sales
- 2.1
- Market cap over revenue
- Per employee
- $419K
- Market cap over employees
- Connections
- 7
- Companies sharing people
Financials
Latest quarter
Q3 2026 figures from Labcorp's earnings release.
Filed 28 Oct 2026
- Revenue
- $3.8B
- Up 6.9% year over year
- Net income
- $263M
- Up 0.7% year over year
- Diluted EPS
- $3.22
- Up 3.3% year over year
- Operating income
- $402M
- Up 1.4% year over year
Reported figures
Figures from the release, against the same period a year earlier.
| Figure | Value | Change |
|---|---|---|
| Revenue | $3.8B | +6.9% |
| Diluted EPS | $3.22 | +3.3% |
| Adjusted EPS | $4.78 | +15% |
| Operating Income | $402M | +1.4% |
| Operating Income as % of Revenue | 10.6% | -0.5 pts |
| Adjusted Operating Income | $570M | +11% |
| Adjusted Operating Income as % of Revenue | 15% | +0.6 pts |
| Net Earnings Attributable to Labcorp Holdings Inc. | $263M | +0.7% |
| Free Cash Flow | $412M | +47% |
| Figure | Value | Change |
|---|---|---|
| Diagnostics Laboratories revenue | $2.9B | +6.5% |
| Diagnostics Laboratories Adjusted Operating Income | $492M | +9.1% |
| Diagnostics Laboratories Adjusted Operating Income as % of Revenue | 16.7% | +0.4 pts |
| Biopharma Laboratory Services revenue | $867M | +8.5% |
| Biopharma Laboratory Services Adjusted Operating Income | $159M | +20% |
| Biopharma Laboratory Services Adjusted Operating Income as % of Revenue | 18.3% | +1.8 pts |
| Figure | Value | Change |
|---|---|---|
| TTM Net Orders | $3.6B | - |
| Backlog | $8.9B | - |
| Next Twelve Months Forecast Backlog Conversion | $2.8B | - |
| Figure | Value | Change |
|---|---|---|
| Revenue guidanceFY 2026 outlook | $14.8B | - |
| Revenue growth guidanceFY 2026 outlook | 6.3% | - |
| Diagnostics Laboratories revenue guidanceFY 2026 outlook | $11.5B | - |
| Diagnostics Laboratories revenue growth guidanceFY 2026 outlook | 5.8% | - |
| Biopharma Laboratory Services revenue guidanceFY 2026 outlook | $3.3B | - |
| Biopharma Laboratory Services revenue growth guidanceFY 2026 outlook | 7.9% | - |
| Adjusted EPS guidanceFY 2026 outlook | $18.50 | - |
| Free Cash Flow guidanceFY 2026 outlook | $1.3B | - |
| Figure | Value | Change |
|---|---|---|
| Dividends paid | $58M | -2.8% |
| Dividends declared per share | $0.72 | - |
Financial history
Twelve months to 30 Sep 2026, from Labcorp's quarterly filings.
Quarters since Dec 2021
- Revenue
- $14.6B
- Up 6.0% on the year before
- Net income
- $1.0B
- 6.9% of revenue
- Free cash flow
- $1.3B
- Operating cash flow less capital spending
- P/E
- 29.6
- Market cap over net income
Quarterly results
Each quarter's revenue, net income and free cash flow.
Dec 2021 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $3.8B | $263M |
| Jun 2026 | $3.7B | $299M |
| Mar 2026 | $3.5B | $278M |
| Dec 2025 | $3.5B | $165M |
| Sep 2025 | $3.6B | $261M |
| Jun 2025 | $3.5B | $238M |
| Mar 2025 | $3.3B | $213M |
| Dec 2024 | $3.3B | $143M |
| Sep 2024 | $3.3B | $169M |
| Jun 2024 | $3.2B | $205M |
| Mar 2024 | $3.2B | $228M |
| Dec 2023 | $3.0B | $-167M |
| Sep 2023 | $3.1B | $183M |
| Jun 2023 | $3.0B | $189M |
| Mar 2023 | $3.8B | $213M |
| Dec 2022 | $3.7B | $76M |
| Sep 2022 | $3.6B | $353M |
| Jun 2022 | $3.7B | $359M |
| Mar 2022 | $3.9B | $492M |
| Dec 2021 | $4.1B | $553M |
Per employee
Twelve months to 30 Sep 2026, over 71,000 employees in Labcorp's latest 10-K.
- Revenue
- $206K
- Operating profit
- $21K
- 10.3% of revenue
- Net income
- $14K
- 6.9% of revenue
Labcorp's market cap since December 2008
Marked weeks are changes in the share count, such as a merger, not market moves.
Weekly, up to 6 Nov 2026
| Week ending | Market cap |
|---|---|
| 6 Nov 2026 | $29.8B |
| 26 Dec 2025 | $21.1B |
| 27 Dec 2024 | $19.3B |
| 29 Dec 2023 | $19.3B |
| 30 Dec 2022 | $20.9B |
| 31 Dec 2021 | $30.1B |
| 25 Dec 2020 | $19.9B |
| 27 Dec 2019 | $16.4B |
| 28 Dec 2018 | $12.6B |
| 29 Dec 2017 | $16.2B |
| 30 Dec 2016 | $13.2B |
| 25 Dec 2015 | $12.6B |
| 26 Dec 2014 | $9.2B |
| 27 Dec 2013 | $8.0B |
| 28 Dec 2012 | $8.1B |
| 30 Dec 2011 | $8.5B |
| 31 Dec 2010 | $8.9B |
| 25 Dec 2009 | $8.1B |
| 26 Dec 2008 | $6.9B |
Download Labcorp's data as JSON, with the weekly market caps in billions of dollars from 5 Dec 2008.
Board and leadership
Board and officers
7 people here also hold roles at other S&P 500 companies.
Board from the proxy filed 10 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (11) | |||||
| Adam H. SchechterChair; President & CEONot independent · since 2013Also at DaVita | |||||
| Kerrii B. AndersonDirectorIndependent · since 2006 · Audit, Nominating and Corporate GovernanceFormer Chief Executive Officer, Wendy's International, Inc.Also at Sherwin-WilliamsOther boards: Worthington Enterprises and Abercrombie & Fitch Co. | |||||
| Carulla Victor BultoDirectorIndependent · since 2025 · AuditPresident, Novartis US | |||||
| Jeffrey A. DavisDirectorIndependent · since 2019 · Audit (chair), Quality and ComplianceFormer Chief Financial Officer, Dollar Tree, Inc.Also at FedEx Freight | |||||
| Kirsten Marie KliphouseDirectorIndependent · since 2022 · AuditFormer President, Google Cloud AmericasAlso at Global Payments | |||||
| Garheng KongLead Independent DirectorIndependent · since 2013 · Compensation and Human Capital, Nominating and Corporate Governance (chair)Managing Partner, HealthQuest CapitalOther boards: Smith & Nephew plc, IKS Health, Lunit and Xeris Biopharma Holdings | |||||
| Peter M. NeupertDirectorIndependent · since 2013 · Nominating and Corporate GovernanceFormer Operating Partner, Health Evolution PartnersOther boards: Adaptive Biotechnologies Corporation and Fortrea Holdings | |||||
| Richelle P. ParhamDirectorIndependent · since 2016 · Compensation and Human Capital (chair), Nominating and Corporate GovernanceFormer President of Global E-Commerce and Business Development, Universal Music GroupAlso at Best Buy | |||||
| Paul RothmanDirectorIndependent · since 2023 · Compensation and Human Capital, Quality and Compliance (chair)Former Dean of the Medical Faculty for Johns Hopkins University School of Medicine and Former Chief Executive Officer of Johns Hopkins MedicineAlso at Merck & Co. | |||||
| John H. SampsonDirectorIndependent · since 2026 · Quality and ComplianceVice Chancellor and Dean, University of Colorado Anschutz School of Medicine, President of CU Medicine | |||||
| Kathryn E. WengelDirectorIndependent · since 2021 · Compensation and Human Capital, Quality and ComplianceExecutive Vice President, Chief Technical Operations & Risk Officer, Executive Committee Member, Johnson & JohnsonAlso at Johnson & Johnson | |||||
| Officers (10) | |||||
| Julia Aijun WangChief Financial Officer, EVPLast filed 13 Feb 2026 | |||||
| Brian J. CaveneyEVP, Pres of BLS, CMO & CSOLast filed 3 Sep 2026 | |||||
| Anita Z. GrahamEVP, CHROLast filed 30 Mar 2026 | |||||
| Kathryn W. KyleEVP, Chief Legal OfficerLast filed 6 Jul 2026 | |||||
| Jonathan C. MeltzerEVP, COOLast filed 3 Sep 2026 | |||||
| Akinbolade OyegunwaEVP, CIO & CTOLast filed 3 Sep 2026 | |||||
| Amy B. SummyEVP, Chief Marketing OfficerLast filed 6 Aug 2026 | |||||
| Sandra D. van der VaartEVP, Corporate AffairsLast filed 30 Mar 2026 | |||||
| Bryan T. VaughnEVP and President, DiagnosticsLast filed 3 Sep 2026 | |||||
| Peter J. WilkinsonSVP, Chief Accounting OfficerLast filed 5 Aug 2026 | |||||
Companies that share people with Labcorp
Each person's title here, then at the other company.
- Best Buy BBY
- Richelle P. Parham: Director here, Director there
- DaVita DVA
- Adam H. Schechter: President & CEO here, Director there
- FedEx Freight FDXF
- Jeffrey A. Davis: Director here, Director there
- Global Payments GPN
- Kirsten Marie Kliphouse: Director here, Director there
- Johnson & Johnson JNJ
- Kathryn E. Wengel: Director here, EVP, Chief TO and Risk Officer there
- Merck & Co. MRK
- Paul Rothman: Director here, Director there
- Sherwin-Williams SHW
- Kerrii B. Anderson: Director here, Director there
Owners and trading
Largest institutional holders
Each fund group's share of Labcorp. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 6 Nov 2025 to 6 Nov 2026
Directors and officers sold $12.4 million of stock in 21 sales and made no open-market purchases in the 12 months to 6 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 3 Nov 2026Sale | Bryan T. VaughnEVP and President, Diagnostics | $108K |
| 30 Oct 2026Sale | Richelle P. ParhamDirector | $389K |
| 17 Aug 2026Sale | Kerrii B. AndersonDirector | $954K |
| 11 Aug 2026Sale | Adam H. SchechterPresident & CEO | $1.5M |
| 4 Aug 2026Sale | Amy B. SummyEVP, Chief Marketing Officer | $283K |
| 3 Aug 2026Sale | Peter J. WilkinsonSVP, Chief Accounting Officer | $439K |
| 2 Jul 2026Sale | Bryan T. VaughnEVP and President, Diagnostics | $67K |
| 2 Jul 2026Sale | Kathryn W. KyleEVP, Chief Legal Officer | $26K |
| 8 Jun 2026Sale | Kathryn W. KyleEVP, Chief Legal Officer | $201K |
| 11 May 2026Sale | Adam H. SchechterPresident & CEO | $1.5M |
Showing 10 of 21 trades
Trades by members of Congress and officials
Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.
Trades from 27 Oct 2023 to 27 Oct 2026
9 people disclosed 22 purchases and 17 sales of Labcorp stock since October 2023.
| Date | Member or official | Amount |
|---|---|---|
| 4 Sep 2026 | Rohit KhannaHouse, D-CA · Bought | $1K to $15K |
| 25 Aug 2026 | April McClain DelaneyHouse, D-MD · Sold | $100K to $250K |
| 7 Aug 2026 | April McClain DelaneyHouse, D-MD · Sold | $1K to $15K |
| 6 Aug 2026 | April McClain DelaneyHouse, D-MD · Sold | $1K to $15K |
| 5 Aug 2026 | April McClain DelaneyHouse, D-MD · Sold | $1K to $15K |
| 11 May 2026 | Donald J TrumpPresident · Bought | $100K to $250K |
| 10 Apr 2026 | Donald J TrumpPresident · Sold | $15K to $50K |
| 27 Mar 2026 | Alan ArmstrongSenate, R-OK · Bought | $1K to $15K |
| 19 Feb 2026 | Tony WiedHouse, R-WI · Bought | $15K to $50K |
| 11 Feb 2026 | April McClain DelaneyHouse, D-MD · Bought | $1K to $15K |
Showing 10 of 39 trades
Workforce and hiring
Workforce
Headcount at 31 Dec 2025
- Employees
- 71,000
Employees, last 10 fiscal years
Down 1.9% in five years, from 72,400 in 2020 to 71,000 in 2025.
During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world.
Open roles
Jobs listed on Labcorp's careers site, each counted once.
Daily, up to 3 Nov 2026
- Open roles
- 1,776
- On 3 Nov 2026
- Change
- -65
- Down 3.5% since 27 Oct 2026
- Top function
- Customer & Retail
- 51% of open roles
- Remote
- 1%
- Fully remote roles
Open roles in detail
27 Oct 2026 to 3 Nov 2026
Most are in the US (91%), then India and China.
| Role | Posted |
|---|---|
| Data Management Associate IBengaluru, India | 3 Nov 2026 |
| Informed Consent Codification AssociateBengaluru, India | 3 Nov 2026 |
| Informed Consent Codification AssociateBengaluru, India | 3 Nov 2026 |
| Informed Consent Codification AssociateBengaluru, India | 3 Nov 2026 |
| Informed Consent Codification AssociateBengaluru, India | 3 Nov 2026 |
| Senior Scientist (Immunoassay)Singapore, Singapore | 3 Nov 2026 |
| Account SpecialistBurlington, North Carolina, United States of America | 2 Nov 2026 |
| Area Dir Business DevelopmentHouston, Texas, United States of America | 2 Nov 2026 |
| Day | Open roles |
|---|---|
| 3 Nov 2026 | 1,776 |
| 2 Nov 2026 | 1,751 |
| 1 Nov 2026 | 1,759 |
| 31 Oct 2026 | 1,768 |
| 30 Oct 2026 | 1,810 |
| 29 Oct 2026 | 1,851 |
| 28 Oct 2026 | 1,846 |
| 27 Oct 2026 | 1,841 |
WARN layoff notices
Notices filed under Labcorp's own name or a subsidiary's listed in its 10-K.
Notices from 7 Nov 2023 to 7 Nov 2026
Labcorp filed 4 notices covering 272 workers since November 2023.
| Notice | Place | Workers |
|---|---|---|
| 5 Mar 2025 | Los Angeles, CA | 73 |
| 16 Sep 2024 | Melbourne, FL | 65 |
| 16 Sep 2024 | Houston, TX | 53 |
| 13 May 2024 | CA | 81 |
Timeline
Leadership changes, layoffs and insider sales
7 Nov 2024 to 7 Nov 2026; insider sales from 6 Nov 2025
4 departures and 5 appointments of directors and officers, WARN layoff notices on 1 day and 5 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Labcorp's insider sales.
Events, newest first
- 11 Aug 2026 Megan D. Bailey resignedExecutive Vice President and President, Central Laboratories and International, effective 4 Sep 2026
- 11 Aug 2026 Brian J. Caveney appointedExecutive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective 1 Sep 2026
- 11 Aug 2026 Adam H. Schechter sold $1.5MPresident & CEO
- 11 May 2026 Adam H. Schechter sold $1.5MPresident & CEO
- 3 Mar 2026 Adam H. Schechter sold $2.4MPresident & CEO
- 11 Feb 2026 Adam H. Schechter sold $1.5MPresident & CEO
- 6 Feb 2026 John H. Sampson appointedMember of the Board, effective 9 Feb 2026
- 9 Dec 2025 Mark Schroeder retiredExecutive Vice President and President, Diagnostics Laboratories and Chief Operations Officer, effective 1 Apr 2026
Showing 8 of 15 events
| Date | Event | Filing |
|---|---|---|
| 11 Aug 2026 | Megan D. Bailey resignedExecutive Vice President and President, Central Laboratories and International, effective 4 Sep 2026 | 8-K |
| 11 Aug 2026 | Brian J. Caveney appointedExecutive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective 1 Sep 2026 | 8-K |
| 11 Aug 2026 | Adam H. Schechter sold $1.5MPresident & CEO | Form 4 |
| 11 May 2026 | Adam H. Schechter sold $1.5MPresident & CEO | Form 4 |
| 3 Mar 2026 | Adam H. Schechter sold $2.4MPresident & CEO | Form 4 |
| 11 Feb 2026 | Adam H. Schechter sold $1.5MPresident & CEO | Form 4 |
| 6 Feb 2026 | John H. Sampson appointedMember of the Board, effective 9 Feb 2026 | 8-K |
| 9 Dec 2025 | Mark Schroeder retiredExecutive Vice President and President, Diagnostics Laboratories and Chief Operations Officer, effective 1 Apr 2026 | 8-K |
| 5 Dec 2025 | D. Gary Gilliland retiredDirector, effective 31 Dec 2025 | 8-K |
| 20 Nov 2025 | Victor Bulto appointedMember of the Board, effective 1 Dec 2025 | 8-K |
| 11 Nov 2025 | Adam H. Schechter sold $1.5MPresident & CEO | Form 4 |
| 5 Mar 2025 | 73 workers in Los Angeles, CAWARN notice, effective 16 May 2025 | WARN |
| 15 Nov 2024 | Glenn Eisenberg retiredExecutive Vice President and Chief Financial Officer, effective 2 Dec 2024 | 8-K |
| 15 Nov 2024 | Glenn Eisenberg appointedSpecial Advisor to Labcorp's Chief Executive Officer, effective 2 Dec 2024 | 8-K |
| 15 Nov 2024 | Julia Wang appointedExecutive Vice President and Chief Financial Officer, effective 2 Dec 2024 | 8-K |